Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults

INTRODUCTION: Adintrevimab is a fully human immunoglobulin G1 extended half-life monoclonal antibody that was developed to have broad neutralization against SARS-CoV, SARS-CoV-2, and other SARS-like CoVs with pandemic potential. Here we report the safety, pharmacokinetics (PK), serum viral neutraliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Pete, Gong, Jean, Narayan, Kristin, Gupta, Deepali, Engler, Frank, Li, Yong, Copans, Amanda, Campanaro, Ed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127981/
https://www.ncbi.nlm.nih.gov/pubmed/37185797
http://dx.doi.org/10.1007/s40121-023-00794-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127981/
https://www.ncbi.nlm.nih.gov/pubmed/37185797
http://dx.doi.org/10.1007/s40121-023-00794-1

Ejemplares similares